Zacks Research Issues Negative Outlook for HALO Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Zacks Research cut their Q1 2025 earnings per share estimates for Halozyme Therapeutics in a research note issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $0.87 per share for the quarter, down from their prior estimate of $0.93. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics’ FY2027 earnings at $7.49 EPS.

A number of other research analysts have also recently commented on HALO. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler boosted their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, Benchmark restated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Trading Up 0.3 %

Shares of HALO opened at $61.06 on Thursday. The stock’s 50-day moving average is $56.50 and its two-hundred day moving average is $54.71. The stock has a market cap of $7.52 billion, a PE ratio of 17.80, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics has a 12 month low of $37.73 and a 12 month high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million.

Insider Buying and Selling at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 1,697 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock worth $1,754,451 over the last quarter. 2.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Janney Montgomery Scott LLC grew its holdings in Halozyme Therapeutics by 38.4% in the 3rd quarter. Janney Montgomery Scott LLC now owns 36,020 shares of the biopharmaceutical company’s stock worth $2,062,000 after buying an additional 9,995 shares in the last quarter. Nations Financial Group Inc. IA ADV grew its holdings in Halozyme Therapeutics by 6.3% in the 3rd quarter. Nations Financial Group Inc. IA ADV now owns 13,734 shares of the biopharmaceutical company’s stock worth $786,000 after buying an additional 815 shares in the last quarter. GSA Capital Partners LLP bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $217,000. Chase Investment Counsel Corp grew its holdings in Halozyme Therapeutics by 2.5% in the 3rd quarter. Chase Investment Counsel Corp now owns 93,601 shares of the biopharmaceutical company’s stock worth $5,357,000 after buying an additional 2,264 shares in the last quarter. Finally, CIBC Asset Management Inc bought a new position in Halozyme Therapeutics in the 3rd quarter worth approximately $211,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.